The Harvard Crimson2h
Cambridge Biopharma Firm Sage Therapeutics Sues Partner Biogen After Buyout Offer
Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
ETF Daily News14d
Sage Therapeutics Initiates Strategic Review Process and Rejects Proposal from Biogen
On January 27, 2025, Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a ...
Business Insider16d
Sage Therapeutics initiates strategic review, rejects Biogen proposal
Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The board intends to evaluate a broad range of ...
The Business Journals16d
Sage rejects Biogen’s buyout offer, but says it's open to deals
The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...
Yahoo Finance16d
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic ...
Eagle-Tribune16d
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage” or “the Company”), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company.
CBC.ca20d
Ford could call Ontario election as early as next week: sources
Read the premier's comments here. Doug Ford could trigger an Ontario election as early as next week, two sources close to the government confirmed to CBC News. Both sources said they expect the ...
FierceBiotech20d
Biogen research team hit by layoffs as company shifts resources to external opportunities
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after receiving an “unsolicited” buyout offer. Biogen and Sage originally ...
Seeking Alpha20d
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid ...
The Motley Fool21d
Why Summit Therapeutics Stock Is Jumping Today
However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.
FiercePharma21d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...